Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial


Jukema J. W., Szarek M., Zijlstra L. E., de Silva H. A., Bhatt D. L., Bittner V. A., ...Daha Fazla

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, cilt.74, sa.9, ss.1167-1176, 2019 (SCI-Expanded) identifier identifier identifier

Özet

BACKGROUND Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined.